SCHEMBL5226751

SCHEMBL5226751

COc1ccc(CC(O)CN2C[CH]N(Cc3ccc(Cl)c(Cl)c3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.54
KCNH2 Q12809 5/20 0.48
CACNA1G O43497 4/20 0.48
LMNA P02545 2/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
MMP1 P03956 1/20 0.41
MMP9 P14780 1/20 0.41
MMP13 P45452 1/20 0.41
ADAM17 P78536 1/20 0.41
HRH1 P35367 2/20 0.40
CCR3 P51677 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MCHR1 Q99705 1/20 0.40
ATM Q13315 1/20 0.39
MAPT P10636 1/20 0.39
SIGMAR1 Q99720 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6258338 0.90 KCNH2 (0.47) CYP2D6KCNH2CACNA1GLMNAMAPK1
SCHEMBL6188797 0.89 CYP2D6 (0.55) CYP2D6KCNH2CACNA1GLMNAMAPK1
SCHEMBL5223079 0.85 CYP2D6 (0.48) CYP2D6KCNH2CACNA1GLMNAMAPK1
SCHEMBL6186218 0.84 CACNA1G (0.52) KCNH2CACNA1GLMNAHTTSMN1; SMN2
SCHEMBL6256607 0.79 CYP2D6 (0.47) CYP2D6KCNH2CACNA1GLMNAMAPK1
SCHEMBL6261178 0.75 MEN1 (0.47) CYP2D6KCNH2CACNA1GLMNAMAPK1
SCHEMBL4500396 0.75 LMNA (0.55) CYP2D6LMNASMN1; SMN2
SCHEMBL5227165 0.74 CACNA1G (0.57) KCNH2CACNA1GLMNAHTTSMN1; SMN2
SCHEMBL5224603 0.74
SCHEMBL6256736 0.72 CYP2D6 (0.55) CYP2D6LMNAMAPK1HTTSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed